These results underline the combined effect of oncolytic virotherapy and dual immune checkpoint inhibition, implying that the FilC/PD-1 virus might offer better therapeutic advantages in HCC by improving anti-tumor immunity and extending longevity (Table 5). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.